PDF herunterladen
Semin Reprod Med 2014; 32(03): 214-221
DOI: 10.1055/s-0034-1371093
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Polycystic Ovary Syndrome in Adolescence

Wendy Vitek
1   Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, New York
,
Kathleen M. Hoeger
1   Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, New York
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
08. April 2014 (online)

    Lizenzen und Reprints

Abstract

Adolescence is a time of rapidly changing reproductive hormones and menstrual patterns making diagnosis of polycystic ovary syndrome (PCOS) challenging in this population. Nonetheless, there is significant concern that the metabolic and reproductive abnormalities that emerge at adolescence associated with a diagnosis of PCOS have lifelong implications for the individual. There are limited data available on the best treatments for the adolescent with PCOS. The focus of treatment is often best served by attention to the individual abnormalities such as menstrual dysfunction, symptoms of androgen excess such as hirsutism and acne, possible metabolic dysfunction primarily seen with concurrent obesity, and concerns related to self-image and mood disorders.

Keywords

treatment - polycystic ovary syndrome - adolescence - obesity
 

  • References

  • 1 Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 2012; 27 (1) 14-24
    CrossrefPubMedGoogle Scholar
  • 2 Lass N, Kleber M, Winkel K, Wunsch R, Reinehr T. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab 2011; 96 (11) 3533-3540
    CrossrefPubMedGoogle Scholar
  • 3 Kiddy DS, Hamilton-Fairley D, Bush A , et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36 (1) 105-111
    CrossrefPubMedGoogle Scholar
  • 4 Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2011; 24 (3) 161-165
    CrossrefPubMedGoogle Scholar
  • 5 Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001; 29 (3) 160-169
    CrossrefPubMedGoogle Scholar
  • 6 Glueck CJ, Goldenberg N, Wang P. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2009; 22 (9) 815-826
    PubMedGoogle Scholar
  • 7 Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002; 87 (4) 1555-1559
    CrossrefPubMedGoogle Scholar
  • 8 Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008. Am J Obstet Gynecol 2012; 207 (5) e1-e8
    PubMedGoogle Scholar
  • 9 Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 2013; 185 (2) E115-E120
    CrossrefPubMedGoogle Scholar
  • 10 Sehovic N, Smith KP. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products. Ann Pharmacother 2010; 44 (5) 898-903
    CrossrefPubMedGoogle Scholar
  • 11 Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 2006; 85 (2) 420-427
    CrossrefPubMedGoogle Scholar
  • 12 Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002; 77 (5) 919-927
    CrossrefPubMedGoogle Scholar
  • 13 Allen HF, Mazzoni C, Heptulla RA , et al. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2005; 18 (8) 761-768
    PubMedGoogle Scholar
  • 14 Matteson KA, Rahn DD, Wheeler II TL , et al; Society of Gynecologic Surgeons Systematic Review Group. Nonsurgical management of heavy menstrual bleeding: a systematic review. Obstet Gynecol 2013; 121 (3) 632-643
    CrossrefPubMedGoogle Scholar
  • 15 Escobar-Morreale HF, Carmina E, Dewailly D , et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2012; 18 (2) 146-170
    CrossrefPubMedGoogle Scholar
  • 16 Smith SR, Piacquadio DJ, Beger B, Littler C. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol Surg 2006; 32 (10) 1237-1243
    PubMedGoogle Scholar
  • 17 Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008; 93 (11) 4299-4306
    CrossrefPubMedGoogle Scholar
  • 18 Mathur R, Levin O, Azziz R. Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome. Ther Clin Risk Manag 2008; 4 (2) 487-492
    PubMedGoogle Scholar
  • 19 Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care 2007; 12 (1) 30-35
    CrossrefPubMedGoogle Scholar
  • 20 Guido M, Romualdi D, Giuliani M , et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004; 89 (6) 2817-2823
    CrossrefPubMedGoogle Scholar
  • 21 Moghetti P, Tosi F, Tosti A , et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85 (1) 89-94
    PubMedGoogle Scholar
  • 22 Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62 (1) 29-38
    CrossrefPubMedGoogle Scholar
  • 23 Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol 2008; 58 (1) 60-62
    CrossrefPubMedGoogle Scholar
  • 24 Castelo-Branco C, Del Pino M. Hepatotoxicity during low-dose flutamide treatment for hirsutism. Gynecol Endocrinol 2009; 25 (7) 419-422
    CrossrefPubMedGoogle Scholar
  • 25 Trent M, Austin SB, Rich M, Gordon CM. Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambul Pediatr 2005; 5 (2) 107-111
    CrossrefPubMedGoogle Scholar
  • 26 Napolitano MA, Hayes S, Bennett GG, Ives AK, Foster GD. Using Facebook and text messaging to deliver a weight loss program to college students. Obesity (Silver Spring) 2013; 21 (1) 25-31
    CrossrefPubMedGoogle Scholar
  • 27 Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 2009; 92 (6) 1966-1982
    CrossrefPubMedGoogle Scholar
  • 28 Moran LJ, Ko H, Misso M , et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet 2013; 113 (4) 520-545
    CrossrefPubMedGoogle Scholar
  • 29 Hutchison SK, Stepto NK, Harrison CL, Moran LJ, Strauss BJ, Teede HJ. Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96 (1) E48-E56
    CrossrefPubMedGoogle Scholar
  • 30 Teede HJ, Joham AE, Paul E , et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity (Silver Spring) 2013; 21 (8) 1526-1532
    CrossrefPubMedGoogle Scholar
  • 31 Nicandri KF, Hoeger K. Diagnosis and treatment of polycystic ovarian syndrome in adolescents. Curr Opin Endocrinol Diabetes Obes 2012; 19 (6) 497-504
    CrossrefPubMedGoogle Scholar
  • 32 Marcovecchio ML, Chiarelli F. Metabolic syndrome in youth: chimera or useful concept?. Curr Diab Rep 2013; 13 (1) 56-62
    CrossrefPubMedGoogle Scholar
  • 33 Steinberger J, Daniels SR, Eckel RH , et al; American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009; 119 (4) 628-647
    CrossrefPubMedGoogle Scholar
  • 34 Rossi B, Sukalich S, Droz J , et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93 (12) 4780-4786
    CrossrefPubMedGoogle Scholar
  • 35 Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91 (2) 492-497
    CrossrefPubMedGoogle Scholar
  • 36 Ehrmann DA. Insulin resistance and polycystic ovary syndrome. Curr Diab Rep 2002; 2 (1) 71-76
    CrossrefPubMedGoogle Scholar
  • 37 Ibáñez L, Valls C, Ferrer A, Ong K, Dunger DB, De Zegher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab 2002; 87 (6) 2870-2874
    CrossrefPubMedGoogle Scholar
  • 38 Dowdy D. Emotional needs of teens with polycystic ovary syndrome. J Pediatr Nurs 2012; 27 (1) 55-64
    CrossrefPubMedGoogle Scholar
  • 39 Trent ME, Rich M, Austin SB, Gordon CM. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2002; 156 (6) 556-560
    CrossrefPubMedGoogle Scholar
  • 40 Dean H. Metformin use in adolescent with PCOS—an invited editorial from the pediatric endocrinology perspective. J Pediatr Adolesc Gynecol 2003; 16 (2) 109-111
    CrossrefPubMedGoogle Scholar
  • 41 Trent ME, Rich M, Austin SB, Gordon CM. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. J Pediatr Adolesc Gynecol 2003; 16 (1) 33-37
    CrossrefPubMedGoogle Scholar
  • 42 Ghazeeri G, Fakih A, Abbas HA, Harajly S, Awwad J. Anxiety, cognitive, and depressive assessment in adolescents with polycystic ovarian syndrome: a pilot study. J Pediatr Adolesc Gynecol 2013; 26 (5) 269-273
    CrossrefPubMedGoogle Scholar
  • 43 Milsom SR, Nair SM, Ogilvie CM, Stewart JM, Merry SN. Polycystic ovary syndrome and depression in New Zealand adolescents. J Pediatr Adolesc Gynecol 2013; 26 (3) 142-147
    CrossrefPubMedGoogle Scholar
  • 44 Harris-Glocker M, Davidson K, Kochman L, Guzick D, Hoeger K. Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. Fertil Steril 2010; 93 (3) 1016-1019
    CrossrefPubMedGoogle Scholar
  • 45 Jakubowski KP, Black JJ, El Nokali NE et al. Parents' readiness to change affects BMI reduction outcomes in adolescents with polycystic ovary syndrome. J Obes 2012; 2012: 298067
    PubMedGoogle Scholar
  • 46 Geier LM, Bekx MT, Connor EL. Factors contributing to initial weight loss among adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2012; 25 (6) 367-370
    CrossrefPubMedGoogle Scholar
  • 47 Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006; 160 (3) 241-246
    CrossrefPubMedGoogle Scholar
  • 48 De Leo V, Musacchio MC, Morgante G, Piomboni P, Petraglia F. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod 2006; 21 (9) 2252-2256
    CrossrefPubMedGoogle Scholar